F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced a conference call and webcast scheduled for November 10, 2021, at 9:00 a.m. EST to discuss its third-quarter 2021 financial results and provide a corporate update.
F-star is focused on developing next-generation immunotherapies for cancer treatment and has four second-generation immuno-oncology therapeutics in clinical trials. The company has a strong intellectual property position with over 500 patents and has secured multiple partnerships addressing significant unmet needs in oncology and other areas.
- F-star is pioneering tetravalent bispecific antibodies for cancer therapy.
- The company has four second-generation immuno-oncology therapeutics in the clinic.
- F-star holds over 500 granted patents and pending patent applications.
- The company has established multiple partnerships in biopharma.
- None.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on November 10, 2021, at 9:00 a.m. EST to review third quarter 2021 financial results and provide a corporate update.
To access the call, participants may join via a live webcast on the Investors & News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following numbers at least 10 minutes prior to the start of the call:
| US/Canada: | 1-833-471-0868 |
| International: | 1-914-987-7751 |
| United Kingdom: | 800 0288438 or 0203 1070289 |
A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/Events and Presentations section on the F-star Therapeutics website.
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. (collectively with its subsidiaries, “F-star” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting the significant unmet needs across several disease areas, including oncology, immunology, and CNS.
For more information visit https://www.f-star.com/ and follow us on LinkedIn and Twitter.
For further information, please contact:
For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@fstar.com
For media inquiries
Helen Shik
Shik Communications LLC
+1 617-510-4373
helen@shikcommunications.com
FAQ
What is the date of F-star Therapeutics' conference call?
What time is the F-star Therapeutics conference call scheduled?
How can I access the F-star Therapeutics conference call?
What topics will be discussed during the F-star conference call?
What is F-star Therapeutics known for?
